Research Analysts Issue Forecasts for FDMT FY2025 Earnings

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) – Equities researchers at Cantor Fitzgerald issued their FY2025 EPS estimates for 4D Molecular Therapeutics in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will earn ($3.46) per share for the year. The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($2.84) per share.

Other equities analysts have also recently issued reports about the company. HC Wainwright restated a “buy” rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Monday, January 13th. Royal Bank of Canada dropped their price target on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a research note on Thursday, November 14th. Bank of America cut their price objective on 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Chardan Capital reissued a “buy” rating and issued a $39.00 price target on shares of 4D Molecular Therapeutics in a research report on Thursday, November 14th. Finally, BMO Capital Markets cut 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $40.00 to $15.00 in a report on Monday, January 13th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, 4D Molecular Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $38.56.

4D Molecular Therapeutics Stock Performance

4D Molecular Therapeutics stock opened at $4.87 on Wednesday. 4D Molecular Therapeutics has a 1 year low of $4.43 and a 1 year high of $36.25. The firm’s 50 day moving average price is $6.40 and its two-hundred day moving average price is $11.10. The firm has a market cap of $225.14 million, a price-to-earnings ratio of -1.71 and a beta of 2.81.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. nVerses Capital LLC acquired a new position in 4D Molecular Therapeutics during the 3rd quarter worth approximately $40,000. Values First Advisors Inc. bought a new position in 4D Molecular Therapeutics during the third quarter worth about $57,000. China Universal Asset Management Co. Ltd. lifted its position in shares of 4D Molecular Therapeutics by 64.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company’s stock valued at $108,000 after acquiring an additional 3,922 shares during the period. Proficio Capital Partners LLC acquired a new position in 4D Molecular Therapeutics during the third quarter valued at approximately $108,000. Finally, Hsbc Holdings PLC acquired a new position in shares of 4D Molecular Therapeutics during the 2nd quarter worth $246,000. 99.27% of the stock is owned by institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.